Actively Recruiting
NEUROwave - Extracorporeal Shock Wave Therapy (ESWT) in Acute Traumatic Complete (AIS A) and Incomplete (AIS B-D) Cross-sectional Lesions on Motor and Sensory Function Within Six Months After Injury
Led by AUVA · Updated on 2024-02-01
246
Participants Needed
15
Research Sites
339 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
It has been hypothesized that there are two mechanisms of acute traumatic spinal cord injury (SCI): the primary mechanical damage and the secondary injury due to additional pathological processes initiated by the primary injury. Neurological damage due to laceration, contusion, distraction or compression of the spinal cord is called ''primary injury''. This mechanical injury leads to a cascade of biochemical and pathological changes, described as ''secondary injury'', which occurs minutes to weeks after the initial trauma and causes further neurological deterioration. This secondary cascade involves vascular changes, an inflammatory response, neurotoxicity, apoptosis and glial scarring, and further compromises neurological impairment after traumatic spinal cord injury. Edema, ischemia and loss of autoregulation continue to spread bi-directionally from the initial lesion along the spinal cord for up to 72 hours after the trauma. It has been postulated that the damage caused by the primary injury mechanism is irreversible and therapeutic approaches in recent years have focused on modulating the secondary injury cascade. Researchers found significantly greater numbers of myelinated fibers in peripheral nerves after a single ESWT application in an experimental model on rats after a homotopic nerve autograft into the sciatic nerve. In another study a spinal cord ischemia model in mice was performed. ESWT was applied immediately after surgery and the treated animals showed a significantly better motor function and decreased neuronal degeneration compared to the control group within the first 7 days after surgery. Researchers investigated the effect of low-energy ESWT for the duration of three weeks on a thoracic spinal cord contusion injury model in rats. Animals in the ESWT group demonstrated significantly better locomotor improvement and reduced neuronal loss compared to the control animals at 7, 35, and 42 days after contusion. It has been postulated previously, that ESWT improves the metabolic activity of various cell types and induces an improved rate of axonal regeneration. ESWT might be a promising therapeutic strategy in the treatment of traumatic SCI. The underlying study aims to investigate the effect of ESWT after acute traumatic spinal cord injury in humans within 48 hours of trauma in order to intervene in the secondary injury phase with the objective to reduce the extent of neuronal damage.
CONDITIONS
Official Title
NEUROwave - Extracorporeal Shock Wave Therapy (ESWT) in Acute Traumatic Complete (AIS A) and Incomplete (AIS B-D) Cross-sectional Lesions on Motor and Sensory Function Within Six Months After Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with acute traumatic spinal injuries who are awake, responsive, and oriented at admission
- Patients from the age of 18 years
- Admission to hospital within 24 hours after injury
- Written consent to participate in the study
- Participation in the Austrian Spinal Cord Injury Study (ASCIS)-Registry (only for the Austrian hospitals)
You will not qualify if you...
- Patients who cannot cooperate or are not capable to give consent to participate
- Serious traumatic brain injuries that prevent accurate participation in study procedures and/or adequacy of informed consent
- Participation in other interventional clinical trials
- Serious concomitant injuries that prevent the neurological initial assessment
- Preexisting neurological conditions that affect the primary endpoint of the study and potentially mask or reduce the therapeutic effect of the ESWT application
- High dose administration of corticosteroids
- Complete spinal cord transection
- Patients with pacemakers or implantable defibrillators
- Patients who are using devices which are sensitive to electromagnetic radiation
- (potential) Pregnancy
- Patients with tumors
- Patients with severe coagulation disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Medical University Innsbruck
Innsbruck, Tyrol, Austria, 6020
Actively Recruiting
2
Rehazentrum Bad Häring
Bad Häring, Austria, 6323
Active, Not Recruiting
3
Landeskarnkenhaus Feldkirch
Feldkirch, Austria, 6807
Actively Recruiting
4
Unfallkrankenhaus Graz
Graz, Austria, 8020
Actively Recruiting
5
Rehazentrum Tobelbad
Graz, Austria, 8144
Active, Not Recruiting
6
Unfallkrankenhaus Klagenfurt
Klagenfurt, Austria, 9020
Actively Recruiting
7
Rehazentrum Weißer Hof
Klosterneuburg, Austria, 3400
Active, Not Recruiting
8
Unfallkrankenhaus Linz
Linz, Austria, 4010
Actively Recruiting
9
Unfallkrankenhaus Salzburg
Salzburg, Austria, 5010
Actively Recruiting
10
Universitätsklinik für Orthopädie und Traumatologie
Salzburg, Austria, 5020
Withdrawn
11
Unfallkrankenhaus St. Pölten
Sankt Pölten, Austria, 3100
Withdrawn
12
Universitätsklinik Wien, AKH
Vienna, Austria, 1090
Actively Recruiting
13
Unfallkrankenhaus Meidling
Vienna, Austria, 1120
Actively Recruiting
14
Unfallkrankenhaus Lorenz Böhler
Vienna, Austria, 1200
Withdrawn
15
SMZ Ost, Donauspital Abteilung für Unfallchirurgie
Vienna, Austria, 1220
Not Yet Recruiting
Research Team
W
Wolfgang Schaden, Dr
CONTACT
I
Iris Leister, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here